Clinical Trials · NCT04194125

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

UnknownPhase 2Octreotide (Unclear)
Phase
Phase 2
Recruitment status
Unknown
Sponsor
University of Warmia and Mazury
Enrollment
25
Start date
Feb 2019
Locations
1 site, Poland
Primary endpoint
PFS - Progression Free Survival
View Octreotide compound reference